474 related articles for article (PubMed ID: 10894863)
1. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group.
Vanhoefer U; Rougier P; Wilke H; Ducreux MP; Lacave AJ; Van Cutsem E; Planker M; Santos JG; Piedbois P; Paillot B; Bodenstein H; Schmoll HJ; Bleiberg H; Nordlinger B; Couvreur ML; Baron B; Wils JA
J Clin Oncol; 2000 Jul; 18(14):2648-57. PubMed ID: 10894863
[TBL] [Abstract][Full Text] [Related]
2. FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer.
Kelsen D; Atiq OT; Saltz L; Niedzwiecki D; Ginn D; Chapman D; Heelan R; Lightdale C; Vinciguerra V; Brennan M
J Clin Oncol; 1992 Apr; 10(4):541-8. PubMed ID: 1548519
[TBL] [Abstract][Full Text] [Related]
3. Phase I-II study of 5-fluorouracil, leucovorin, doxorubicin, methotrexate, and long-term oral etoposide (FLAME) in unresectable or metastatic gastric cancer.
Bjarnason GA; Cripps C; Goel R; Fine S; Oza AM; Skillings JR; Kerr I; Germond CJ; Moore MJ; Maroun JA; Franssen E; Dulude H
Am J Clin Oncol; 1998 Dec; 21(6):537-42. PubMed ID: 9856651
[TBL] [Abstract][Full Text] [Related]
4. New developments in the treatment of gastric carcinoma.
Wilke H; Preusser P; Fink U; Achterrath W; Meyer HJ; Stahl M; Lenaz L; Meyer J; Siewert JR; Geerlings H
Semin Oncol; 1990 Feb; 17(1 Suppl 2):61-70. PubMed ID: 2305269
[TBL] [Abstract][Full Text] [Related]
5. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.
Webb A; Cunningham D; Scarffe JH; Harper P; Norman A; Joffe JK; Hughes M; Mansi J; Findlay M; Hill A; Oates J; Nicolson M; Hickish T; O'Brien M; Iveson T; Watson M; Underhill C; Wardley A; Meehan M
J Clin Oncol; 1997 Jan; 15(1):261-7. PubMed ID: 8996151
[TBL] [Abstract][Full Text] [Related]
6. Etoposide, doxorubicin and cisplatin alternating with 5-fluorouracil, doxorubicin and high-dose methotrexate in patients with advanced adenocarcinoma of the stomach or the gastroesophageal junction.
Bar Sela G; Tsalic M; Gaitini D; Steiner M; Haim N
J Chemother; 2002 Dec; 14(6):623-6. PubMed ID: 12583555
[TBL] [Abstract][Full Text] [Related]
7. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group.
Wils JA; Klein HO; Wagener DJ; Bleiberg H; Reis H; Korsten F; Conroy T; Fickers M; Leyvraz S; Buyse M
J Clin Oncol; 1991 May; 9(5):827-31. PubMed ID: 2016625
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma.
Cocconi G; Carlini P; Gamboni A; Gasperoni S; Rodinò C; Zironi S; Bisagni G; Porrozzi S; Cognetti F; Di Costanzo F; Canaletti R; Ruggeri EM; Camisa R; Pucci F;
Ann Oncol; 2003 Aug; 14(8):1258-63. PubMed ID: 12881389
[TBL] [Abstract][Full Text] [Related]
9. The treatment of advanced gastric cancer.
Wils J
Semin Oncol; 1996 Jun; 23(3):397-406. PubMed ID: 8658224
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemotherapy with P-ELF (cisplatin, etoposide, leucovorin, 5-fluorouracil) followed by radical resection in patients with initially unresectable gastric adenocarcinoma: a phase II study.
Gallardo-Rincón D; Oñate-Ocaña LF; Calderillo-Ruiz G
Ann Surg Oncol; 2000; 7(1):45-50. PubMed ID: 10674448
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil.
Kelsen D; Karpeh M; Schwartz G; Gerdes H; Lightdale C; Botet J; Lauers G; Klimstra D; Huang Y; Saltz L; Quan V; Brennan M
J Clin Oncol; 1996 Jun; 14(6):1818-28. PubMed ID: 8656250
[TBL] [Abstract][Full Text] [Related]
12. Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer.
Moehler M; Eimermacher A; Siebler J; Höhler T; Wein A; Menges M; Flieger D; Junginger T; Geer T; Gracien E; Galle PR; Heike M
Br J Cancer; 2005 Jun; 92(12):2122-8. PubMed ID: 15942629
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin, etoposide, and weekly high-dose 5-fluorouracil and leucovorin infusion (PE-HDFL)--a very effective regimen with good patients' compliance for advanced gastric cancer.
Cheng AL; Yeh KH; Lin JT; Hsu C; Liu MY
Anticancer Res; 1998; 18(2B):1267-72. PubMed ID: 9615799
[TBL] [Abstract][Full Text] [Related]
14. A phase II trial of etoposide, leucovorin and 5-fluorouracil (ELF) in patients with advanced gastric cancer.
Au E; Koo WH; Tan EH; Ang PT
J Chemother; 1996 Aug; 8(4):300-3. PubMed ID: 8873837
[TBL] [Abstract][Full Text] [Related]
15. Etoposide, leucovorin and 5-fluorouracil in advanced gastric cancer: a phase II study.
Van Cutsem E; Filez L; Dewyspelaere J; Penninckx F; Janssens J
Anticancer Res; 1995; 15(3):1079-80. PubMed ID: 7645929
[TBL] [Abstract][Full Text] [Related]
16. Etoposide, l-leucovorin and fluorouracil (ELF) regimen in metastatic gastric cancer: a phase II study.
Adamo V; Scimone A; Maisano R; Altavilla G; Ferraro G; Laudani A; Pergolizzi S; Zanghì M
J Chemother; 1999 Feb; 11(1):74-7. PubMed ID: 10078785
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy in gastric cancer: an economic evaluation of the FAM (5-fluorouracil, adriamycin, mitomycin C) versus ELF (etoposide, leucovorin, 5-fluorouracil) regimens.
Norum J; Angelsen V
J Chemother; 1995 Oct; 7(5):455-9. PubMed ID: 8596132
[TBL] [Abstract][Full Text] [Related]
18. Sequence-dependent toxicity profile in modified FAMTX (fluorouracil-adriamycin-methotrexate) chemotherapy with lenograstim support for advanced gastric cancer: a feasibility study.
Westermann AM; Taal BG; Swart M; Boot H; Craanen M; Gerritsen WR
Pharmacol Res; 2000 Aug; 42(2):151-6. PubMed ID: 10887044
[TBL] [Abstract][Full Text] [Related]
19. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial.
Waters JS; Norman A; Cunningham D; Scarffe JH; Webb A; Harper P; Joffe JK; Mackean M; Mansi J; Leahy M; Hill A; Oates J; Rao S; Nicolson M; Hickish T
Br J Cancer; 1999 Apr; 80(1-2):269-72. PubMed ID: 10390007
[TBL] [Abstract][Full Text] [Related]
20. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer.
Murad AM; Santiago FF; Petroianu A; Rocha PR; Rodrigues MA; Rausch M
Cancer; 1993 Jul; 72(1):37-41. PubMed ID: 8508427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
